Key result
Dexmedetomidine infusion during CABG surgery did not significantly affect ACE-III scores at discharge compared to typical anaesthesia, though scores increased from baseline at 3 months (p=0.000).
Why the study?
Postoperative neurological deficits and cognitive decline remain concerns after cardiac surgery, and dexmedetomidine may offer neuroprotection.
Does dexmedetomidine improve cognitive function (ACE-III score) at discharge in patients undergoing coronary artery bypass graft surgery with extracorporeal circulation?
Population
46 patients undergoing coronary artery bypass graft surgery with extracorporeal circulation
Comparison
Dexmedetomidine infusion vs typical anaesthesia
Design
Randomised controlled trial
Follow-up
3 months after discharge
Authors
Loading...
Dexmedetomidine offers no cognitive benefit at discharge after CABG; challenges neuroprotective assumptions while extending biomarker observations without clinical translation.
RCT (n=46)
Randomized
Does dexmedetomidine improve cognitive function (ACE-III score) at discharge in patients undergoing coronary artery bypass graft surgery with extracorporeal circulation?
The administration of dexmedetomidine as an adjuvant to anaesthesia during CABG increases MMP-12 and MBP levels but does not impact neurocognitive outcomes at discharge or 3 months postoperatively.
Kowalczyk et al. (2022) conducted an RCT in Coronary artery bypass graft surgery with extracorporeal circulation (n=46). Dexmedetomidine vs. Typical anaesthesia was evaluated on ACE-III score at discharge. Dexmedetomidine infusion during CABG surgery did not significantly affect ACE-III scores at discharge compared to typical anaesthesia, though scores increased from baseline at 3 months (p=0.000).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: